Companies Must Refine Patient Selection In Studies To Maximize Payment
This article was originally published in The Gray Sheet
Executive Summary
In the post-health-care-reform environment, device and drug companies must carefully consider what types of patients they include in their clinical trials to maximize chances for reimbursement, according to analysts from Parexel Consulting